GPHC is a modern, fast-growing Russian pharmaceutical company founded in 2020. Step by step we implement our long-term corporate strategy aimed at developing, registering, production, marketing and promoting our own drugs as well as original drugs of domestic and foreign partners. Our pharmaceuticals are widely used in anesthesiology, resuscitation and intensive medicine, surgery, oncology and diabetology.
GPHC is a team of professionals. Our key competence is the experience of quick introduction of complex hospital drugs into the Russian market.
The company's mission
Our mission is to make complicated and knowledge-intensive medicines available in order to reduce the recovery time of patients.
Our partners
Our partners are organizations and people behind them who are involved in providing the healthcare system with medicines and medical products.
Our partners are manufacturing sites of pharmaceutical substances, finished medicines and medical products, distribution and logistics companies, and of course medical organizations and healthcare professionals providing medical care to the population of our country.
We understand the social responsibility of our activities – behind each drug there is a patient whose health depends on the quality of our products and their timely delivery. Therefore, we create the most convenient conditions for providing the necessary medicines in the shortest possible time so that each patient receives timely and high-quality pharmacotherapy.
Priorities
- Balanced product portfolio. The company forms a portfolio based on the demand for medicines in the healthcare system. As part of the development plan, GPHC plans to register and produce about 25 medicines used in hospital practice at the first stage.
- Quality. The presented range of medicines is produced at the largest domestic and foreign production sites, in accordance with international quality standards in the pharmaceutical industry – GMP (Good Manufacturing Practices) of the EAEU with a built-in quality management system (QMS) and continuous pharmacovigilance.
- Geography of presence. GPHC supplies its own and partner medicines to all regions of the Russian Federation. The company plans to launch both its own products and innovative partner products to the market of the Eurasian Economic Union countries in the next two years.
- Import substitution. The company plans to launch its own production of sterile liquid and solid dosage forms in order to meet the high demand for high-quality hospital drugs in the domestic market. The Development Department of GPHC constantly analyzes the pharmaceutical market and selects the most popular areas for import substitution.
